

## Regional pattern of the molecular types of *Cryptococcus neoformans* and *Cryptococcus gattii* in Brazil

Luciana Trilles<sup>1</sup>, Márcia dos Santos Lazéra, Bodo Wanke, Raquel Vasconcelos Oliveira<sup>2</sup>, Gláucia Gonçalves Barbosa, Marília Martins Nishikawa<sup>3</sup>, Bernardina Penarrieta Morales, Wieland Meyer<sup>1</sup>

Laboratório de Micologia <sup>2</sup>Centro de Estatística e Documentação, Instituto de Pesquisa Clínica Evandro Chagas-Fiocruz, Av. Brasil 4365, 21040-900 Rio de Janeiro, RJ, Brasil <sup>3</sup>Molecular Mycology Research Laboratory, Center for Infectious Diseases and Microbiology, Westmead Hospital, Westmead Millennium Institute, Western Clinical School, University of Sydney, Sydney, Austrália <sup>3</sup>Departamento de Microbiologia, Instituto Nacional de Controle de Qualidade em Saúde-Fiocruz, Rio de Janeiro, RJ, Brasil

The molecular types of 443 Brazilian isolates of *Cryptococcus neoformans* and *Cryptococcus gattii* were analyzed to determine their geographic distribution within Brazil and their underlying host conditions. The following data, imported from previous epidemiological studies as well as two culture collections, were analyzed for: place of isolation, source (clinical or environmental), host risk factors, species, serotype, mating type, and molecular type. Molecular typing by PCR-fingerprinting using primers for the minisatellite-specific core sequence of the wild-type phage M13 or microsatellites [(GACA)<sub>4</sub>, (GTG)<sub>3</sub>], restriction fragment length polymorphism of URA5 gene analysis, and/or amplified fragment length polymorphism (AFLP) identified eight major genotypes: VNI/AFLP1, VNII/AFLP1A, VNIII/AFLP2, and VNIV/AFLP3 for *C. neoformans*, and VGI/AFLP4, VGII/AFLP6, VGIII/AFLP5, and VGIV/AFLP7 for *C. gattii*. The most common molecular type found in Brazil was VNI (64%), followed by VGII (21%), VNII (5%), VGIII (4%), VGI and VNIV (3% each), and VNIII (< 1%). Primary cryptococcosis caused by the molecular type VGII (serotype B, MATa) prevails in immunocompetent hosts in the North and Northeast regions, disclosing an endemic regional pattern for this specific molecular type in the Northern Brazil.

Key words: *Cryptococcus neoformans* - *Cryptococcus gattii* - molecular types - epidemiology - Brazil

Cryptococcosis is a life-threatening, systemic mycosis affecting humans and animals. It is acquired by inhalation of viable propagules from the environment, and the most common clinical manifestation of cryptococcosis is meningoencephalitis (Lin & Heitman 2006). Cryptococcosis is caused by two different species of the genus *Cryptococcus*: *C. neoformans* (serotypes A, D, and hybrid AD) and *C. gattii* (serotypes B and C) (Kwon-Chung et al. 2002). While *C. neoformans* infections occur worldwide and are an important cause of morbidity and mortality in immunocompromised hosts (especially AIDS-patients), *C. gattii* usually infects normal hosts (Kwon-Chung & Bennett 1992, Lazéra et al. 2005) and is considered to be a tropical disease. The ongoing Vancouver Island outbreak in a temperate climate, however, suggests that *C. gattii* can adapt to new environments (Kidd et al. 2004).

In Brazil, cryptococcosis caused by *C. neoformans* occurs in all regions; however, *C. gattii* behaves as a primary pathogen infecting native immunocompetent hosts and mainly infects young people and children in the North and Northeast (NE) regions of Brazil. In this

group of patients, the infection is characterized by a high lethality rate that ranges from 40.6% to 56% (Correa et al. 1999, Lazéra et al. 2005) and frequently causes incapacity (e.g., visual deficits or blindness) and hydrocephalus (Rozenbaum & Gonçalves 1994, Nishikawa et al. 2003). Brazilian epidemiological data suggest a geographic, macroregional, north-south trend in *C. gattii* infections in Brazil. The Northern macro region (NM), which is comprised of the states of Amazonas, Roraima, Pernambuco, Piauí, and Bahia, is endemic for *C. gattii*. The Southern macro region (SM), which are represented by the states of Mato Grosso do Sul, Minas Gerais, São Paulo (SP), Rio de Janeiro (RJ), Paraná, and Rio Grande do Sul (RS), show sporadic infections by *C. gattii*.

Serotyping was largely used for epidemiological studies of *C. gattii* and *C. neoformans*, but the lack of an available commercial serotyping kits and the search for a more reliable technique led to an increased use of molecular tools. Additionally, the analysis of genotypes within a species could answer several questions that may impact management, therapy, surveillance, and prophylactic actions. An attempt to standardize a technique for a global molecular epidemiological survey of the agents of cryptococcosis identified eight major molecular types via PCR fingerprinting with the minisatellite-specific core sequence of the wild-type phage M13 or microsatellites [(GACA)<sub>4</sub>, (GTG)<sub>3</sub>]. Thus, *C. neoformans* was grouped into the types VNI (serotype A), VNII (serotype A), VNIII (serotype AD), and VNIV (serotype D); *C. gattii* was grouped into the types VGI, VGII, VGIII, and VGIV (serotypes B and C) (Meyer et al. 1999). This

Financial support: CAPES, NH&MRC (ID 990738; ID 352303)

+ Corresponding author: luciana.trilles@ipecc.fiocruz.br

Received 30 January 2008

Accepted 9 July 2008

grouping has been confirmed by others using different techniques, such as amplified fragment length polymorphism analysis (AFLP) (Boekhout et al. 2001), restriction fragment length polymorphism analysis (RFLP) of *URA5* and *PLB1* genes (Latouche et al. 2003, Meyer et al. 2003), and multilocus sequence typing (MLST) (Litvinseva et al. 2006). Recently, AFLP and MLST have revealed the existence of a new molecular type of *C. neoformans* in Botswana (genotype VNB) that seems to be geographically restricted to sub-Saharan Africa (Litvinseva et al. 2006).

Although several previous studies have analyzed the molecular types of Brazilian isolates according to the previously described typing system (VNI/AFLP1, VNII/AFLP1A, VNIII/AFLP2, VNIV/AFLP3, VGI/AFLP4, VGII/AFLP6, VGIII/AFLP5, and VGIV/AFLP7 types), they demonstrated only the presence of *C. neoformans* and *C. gattii* in certain cities or states (Casali et al. 2003, Igreja et al. 2004, Abegg et al. 2006, Matsumoto et al. 2007). Even when more than one region was analyzed, the number of isolates was limited (Trilles et al. 2003).

In the current study, the main objectives were to obtain an up-to-date picture of the molecular type distribution of *C. gattii* and *C. neoformans* in Brazil and correlate the genotypes to geographic regions and host conditions by reanalyzing all of data from previously published cryptococcal strains and combining them with data obtained from new strains using statistics and descriptive analysis.

#### MATERIALS AND METHODS

Data from 356 Brazilian isolates were imported from different sources: (i) previous epidemiological studies (Boekhout et al. 2001, Casali et al. 2003, Trilles et al. 2003, Meyer et al. 2003, Igreja et al. 2004, Katsu et al. 2004, Ribeiro et al. 2006), (ii) the database of the Cryptococcal Culture Collection at Laboratório de Micologia, Instituto de Pesquisa Clínica Evandro Chagas, RJ, and (iii) the database of the Australian Medical Fungal Collection, at the Molecular Mycology Research Laboratory at Westmead Hospital, Sydney, Australia.

The data collected for the current analysis included: place of isolation, source (clinical or environmental), host risk factors, species, serotype, mating type, and molecular type identified by PCR-fingerprinting, *URA5*-RFLP according to Meyer et al. (2003), or AFLP according to Boekhout et al. (2001). In addition to the imported data described above, we determined the mating type, serotype, molecular type, and polymorphisms of additional 87 *C. gattii* and *C. neoformans* isolates.

**Serotyping** - Serotyping was carried out using the slide agglutination test according to the manufacturer's instructions (Crypto Check Iatron RM 304-K kit; Iatron Laboratories, Tokyo, Japan).

**Molecular typing** - The 87 clinical and environmental Brazilian isolates were typed by *URA5*-RFLP and PCR-fingerprinting using the minisatellite-specific core sequence of the wild-type phage M13. The following standard strains representing each molecular type were included in the analysis: WM 148 (serotype A, VNI/

AFLP1), WM 626 (serotype A, VNII/AFLP1A), WM 628 (serotype AD, VNIII/AFLP2), WM 629 (serotype D, VNIV/AFLP3), WM 179 (serotype B, VGI/AFLP4), WM 178 (serotype B, VGII/AFLP6), WM 175 (serotype B, VGIII/AFLP5), and WM 779 (serotype C, VGIV/AFLP7) (Meyer et al. 2003). The DNA was extracted as previously described (Meyer et al. 1999). The isolates were grown on Sabouraud's dextrose agar at 37°C for 48 h. The tube containing the yeast cell pellet was frozen in liquid nitrogen. The pellet was ground with a miniature pestle, and 500 µl of cell lysis solution (0.5% sodium dodecyl sulfate, 1.4% NaCl, 0.73% EDTA, and Tris-HCl 0.2M) was added to the frozen, ground cells. The tubes were incubated for 5 min at room temperature with constant shaking, and 500 µl phenol:chloroform:isoamyl alcohol (v:v:v 25:24:1) was added and mixed thoroughly for 2 min to obtain a homogenous suspension. The tubes were centrifuged for 20 min at 16,110 g. After centrifugation, the upper aqueous layer was transferred to a new tube, an equal volume of chloroform:isoamyl alcohol (v:v 24:1) was added, and the mixture was shaken and centrifuged. To precipitate the genomic DNA, an equal volume of isopropanol was added to the supernatant. The mixture was then gently shaken and incubated at -20°C for at least 1 h or overnight. The DNA pellet was washed with 70% ethanol and suspended in 200 µl sterile, deionized water at 4°C overnight.

PCR of the *URA5* gene was performed in a final volume of 50 µl. Each reaction contained 50 ng of DNA, 1 X PCR buffer [160 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 670 mM Tris-HCl (pH8.8 at 25°C), 0.1% Tween-20 - Biotline], 0.2 mM each of dATP, dCTP, dGTP, and dTTP (Roche Diagnostics GmbH), 3 mM magnesium chloride, 1.5 U BioTaq DNA polymerase (Biotline), and 50 ng of each primer *URA5* (5' ATGTCCTCCCAAGCCCTCGACTCCG 3') and *SJ01* (5' TTAAGACCTCTGAACACCGTACTC 3') (Meyer et al. 2003). PCR was performed for 35 cycles in a Perkin-Elmer thermal cycler (model 480) at 94°C with a 2 min initial denaturation, 45 s denaturation at 94°C, 1 min annealing at 61°C, 2 min extension at 72°C, and final extension cycle for 10 min at 72°C. A total of 30 µl of PCR products were double digested with *Sau96I* (10 U/µl) and *HhaI* (20 U/µl) for 3 h, and the fragments were separated by 3% agarose gel electrophoresis at 100 V. RFLP patterns were assigned visually by comparison with patterns obtained from standard strains (VNI-VNIV and VGI-VGIV).

PCR-fingerprinting reactions were carried out in a volume of 50 µl containing 25 ng genomic DNA, 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.2 mM each of the dATP, dCTP, dGTP, and dTTP (Roche Diagnostics GmbH, Mannheim, Mannheim, Germany), 3 mM magnesium acetate, 30 ng primer (5' GAGGGTGGCG-GTTCT 3'), and 2.5 U AmpliTaq DNA polymerase (Applied Biosystems, Foster City, CA). PCR was performed for 35 cycles in a Perkin-Elmer thermal cycler (model 480) with a 20 s denaturation at 94°C, 1 min annealing at 50°C, 20 s extension at 72°C, and final extension cycle for 6 min at 72°C. Amplification products were concentrated to a volume of approximately 15 µl and separated by electrophoresis on 1.4% agarose gels stained with

ethidium bromide in 1 X Tris-borate-EDTA (TBE) buffer at 70 V for 9 h, and they were visualized under a UV light (Meyer et al. 2003). PCR-fingerprinting profiles were visually compared to the standard strains to determine the molecular types. The genetic relationships of the isolates were analyzed using the 1D gel analysis module (BioGalaxy, BioAware, Hannut, Belgium) in BioMICS version 7.5.30 (BioAware). Similarity coefficients were calculated by using the Dice algorithm, and cluster analyses were performed by the Unweighted Pair Group Method with the Arithmetic mean (UPGMA).

AFLP analysis was performed according to the AFLP Microbial Fingerprinting Protocol of the manufacturer (Applied Biosystems), and we used *MseI* and *EcoRI* for the DNA restriction digestion (Boekhout et al. 2001). The restriction ligation was performed using 1 unit *MseI*, 5 units *EcoRI*, and 3 units T4 DNA ligase. The first PCR procedure was performed with two pre-selective primers (*EcoRI* core sequence and *MseI* core sequence) and the AFLP Amplification Core Mix from the AFLP Microbial Fingerprinting Kit according to the manual. A second PCR procedure used more selective primers (*EcoRI*-AC FAM and *MseI*-G).

**Mating type** - The mating type was determined by PCR. MAT alpha-specific mating type primers were MatalphaF (5' CTCCTACTGCCATCTTCACCA 3') and MatalphaR (5' GACACAAAGGGTCATGCCA 3'), and the amplification reactions were carried out according to the procedure in Chaturvedi et al. (2000). MAT a-specific mating type primers were MFa2U (5' ACACCGC-CTGTTACAATGGAC 3') and MFa2L (5' CAGCGTTT-GAAGATGGACTTT 3') (Fraser et al. 2003), and the amplifications reactions were performed according to the procedure in Halliday and Carter (2003).

**Statistical analysis** - Statistical analysis of 443 *C. neoformans* and *C. gattii* isolates was performed using SPSS version 11.0 software, and a p-value < 0.05 was used to define significance. The most representative molecular types in terms of the numbers of isolates were included in the logistical analysis. Univariate analysis was performed using the Fisher's exact and chi-square tests. Odds ratio (OD) and 95% confidence intervals was calculated to assess the univariate risk of a particular molecular type or species occurring in a certain geographic area. The variables selected for the current study were source, host factors, and region (NM or SM). Host factors were analyzed according to the immunological status of the patient as either immunocompetent, HIV negative with no other conditions or immunocompromised, HIV positive or other conditions (e.g., corticotherapy and tumor). The complete data of the isolates are shown in the supplementary data. A multivariate logistic regression model was used to analyze 291 clinical samples and was calculated with SAS software version 8.0 using the Genmod procedure. The log-binomial model was used for estimating the adjusted relative risk of the most common molecular type of each species occurring in different host conditions as well as different Brazilian regions. The variables for which the Wald test showed a p < 0.05 were included in the final model. Two models were tested separately to examine the interactions be-

tween host factors and the macro region (i.e., VNI was compared to all other molecular types, and VGII was compared to all other molecular types).

## RESULTS

A total of 443 *C. neoformans* (n = 320) and *C. gattii* (n = 123) isolates from all Brazilian regions, representing 11 Brazilian states, were analyzed (Fig. 1). Data from 356 isolates were imported from previous studies and that from 87 isolates were newly typed using the molecular tools described above. Out of the 320 *C. neoformans* isolates, 251 were clinical and 69 environmental isolates. Out of the 123 *C. gattii* isolates, 86 were clinical (84 human and 2 veterinary) and 37 were environmental isolates.

Information regarding geographic origin was not available for two isolates (0.5%). Mating type data was available for 262 (59.1%) isolates, and 249 (95%) of these were of mating type alpha. Ten isolates were of mating type a (5 VNIV environmental and 5 VGII clinical isolates, all from the NM). Host risk factor data were available for 293 of the 335 (87%) clinical isolates. The distribution of the molecular types of the *Cryptococcus* species complex in Brazil according to geographic region, mating type, source, and host factors is shown on Table I.

Overall, the most common molecular types were VNI (64%) and VGII (21%), followed by VNII (5%), VGIII (4%), VGI and VNIV (3% each), and VNIII (< 1%). The molecular type VGIV was not identified among the studied Brazilian isolates. Fig. 1 shows the distribution of the molecular types according to the Brazilian states included in the analysis. Fig. 2A demonstrates the RFLP profiles of the eight molecular types (VNI-VNIV, VGI-VGIV) resulting from the *URA5*-RFLP technique using the standards isolates, and Fig. 2B shows the PCR fingerprinting profiles from the eight standards isolates as well as a representative example of the Brazilian isolates. Univariate analysis of the dataset showed that the OD of




Fig. 1: map of Brazil showing the two macro regions (Northern and Southern macro regions) and the distribution of the molecular types and number of isolates according to the states involved in the study: AM: Amazonas; BA: Bahia; MG: Minas Gerais; MS: Mato Grosso do Sul; PE: Pernambuco; PI: Piauí; PR: Paraná; RJ: Rio de Janeiro; RR: Roraima; RS: Rio Grande do Sul; SP: São Paulo.

TABLE I  
Distribution of the molecular types according the main characteristics of 443 Brazilian isolates included in this study

| Characteristics       | Molecular types – n (%) |           |          |            |          |         |           | Total |
|-----------------------|-------------------------|-----------|----------|------------|----------|---------|-----------|-------|
|                       | VGI                     | VGII      | VGIII    | VNI        | VNII     | VNIII   | VNIV      |       |
| Geographic region     |                         |           |          |            |          |         |           |       |
| Northern Macro region | -                       | 68 (63.6) | 4 (3.7)  | 30 (28)    | -        | -       | 5 (4.7)   | 107   |
| Southern Macro region | 14 (4.2)                | 24 (7.2)  | 12 (3.6) | 252 (75.4) | 22 (6.6) | 1 (0.3) | 9 (2.7)   | 334   |
| Mating Type           |                         |           |          |            |          |         |           |       |
| Alpha                 | 9 (3.6)                 | 63 (25.3) | 12 (4.8) | 151 (60.6) | 5 (2.0)  | -       | 9 (3.6)   | 249   |
| A                     | -                       | 5 (50)    | -        | -          | -        | -       | 5 (50)    | 10    |
| Alpha/a               | -                       | -         | -        | 3 (100)    | -        | -       | -         | 3     |
| Source                |                         |           |          |            |          |         |           |       |
| Clinical              | 14 (4.2)                | 54 (16.1) | 16 (4.8) | 234 (69.9) | 17 (5.1) | -       | -         | 335   |
| Environmental         | 1 (0.9)                 | 36 (34)   | -        | 49 (46.2)  | 5 (4.7)  | 1 (0.9) | 14 (13.2) | 106   |
| Veterinary            | -                       | 2 (100)   | -        | -          | -        | -       | -         | 2     |
| Host Factors          |                         |           |          |            |          |         |           |       |
| Immunocompetent       | 5 (11.9)                | 25 (59.5) | 6 (14.3) | 6 (14.3)   | -        | -       | -         | 42    |
| Immunocompromised     | -                       | 9 (3.6)   | 3 (1.2)  | 222 (88.4) | 17 (5.8) | -       | -         | 251   |




Fig. 2: A: restriction fragment length polymorphism (RFLP) profiles of *URA5* gene obtained by double digestion of the gene with *Sau96I* and *HhaI* of the standards isolates representing the eight molecular types VNI-VNIV and VGI-VGIV; B: banding patterns generated by PCR-fingerprints with the primer M13 obtained from a selection of Brazilian *C. neoformans* and *C. gattii* isolates, given as a representative example for the patterns obtained from clinical and environmental isolates. Standard patterns obtained from the reference strains of the eight major molecular types by PCR-fingerprinting with the microsatellite specific primer M13 (right-hand side of 2B).

an isolate being molecular type VNI or VGII (compared to all other molecular types) varied according to the region (NM or SM) when both clinical and environmental datasets were analyzed separately. Investigation of clinical (OD 9.6;  $p < 0.001$ ) and environmental (OD 2.4;  $p < 0.001$ ) samples suggests that the molecular type VGII is more likely to occur in the NM. On the contrary, VNI isolates are more likely to occur in the SM and show an OD of 1.5 for both clinical and environmental isolates ( $p < 0.001$  and  $p = 0.018$ , respectively). *C. gattii* is 4.4 times more likely to occur in the NM, whereas *C. neoformans* is 1.6 times more likely to occur in the SM ( $p < 0.001$ ).

The Wald test for the VNI log-binomial model revealed that host factors were significant ( $p < 0.05$ ), whereas the macro region was not important for the occurrence of this molecular type in Brazil ( $p > 0.05$ ). VNI was five times more likely than the other molecular types to infect immunocompromised hosts (Table II). When the major molecular type VGII was analyzed, the interaction analysis showed a significant correlation between host factors and macro region. This reflects a demographic pattern of distribution, because the majority of immunocompromised patients (mainly AIDS patients) live in big cities. The largest Brazilian cities

are located in the SM. This correlation may partially explain the predominance of VGII (*C. gattii*) in the NM. However, the Wald test for the VGII log-binomial model showed that the geographic region and host condition were significant predictors ( $p = 0.006$ ) (Table III). Although it is slightly higher, the relative risk is quite similar to the adjusted relative risk. Immunocompetent hosts are ten times more likely to be infected by VGII than by all other molecular types. The molecular type VGII is 16 times more likely to occur in the NR (Table III). Nine out of 34 VGII (26%) clinical isolates were associated with HIV infections; two of these were from the NM and seven were from the SM.

Molecular polymorphisms identified via PCR-fingerprinting using the primer M13 grouped the 87 isolates into the major molecular types of VNI, VNII, VNIV, VGI, and VGII (Fig. 4). Overall, the similarity of the *C. neoformans* isolates was 87%, whereas that of the *C. gattii* isolates was 77%. According to the banding pattern, VNI isolates ( $n = 25$ ) were divided into six subtypes: one major group comprised 50% of the VNI isolates, three groups contained three or four isolates, and two clinical isolates clustered individually. The VNII isolates ( $n = 3$ ) showed individual patterns. The only three VNIV isolates analyzed by PCR-fingerprinting showed a unique, identical banding pattern. The VGI isolates ( $n = 13$ ) were all from RJ (SN) and were divided into one major group (10 isolates), and three clinical isolates showed individual banding patterns. The highest degree of polymorphism was observed among the VGII isolates, which showed 14 individual patterns (1 major group with 8 isolates and a second group with 6 isolates). There was no association between these subtypes and their geographical distribution.

**DISCUSSION**

In this study, two major epidemiological trends were identified in Brazil: *C. gattii* predominantly occurred in the NM (OD 5.4;  $p < 0.001$ ), and *C. neoformans* predominantly occurred in the SM (OD 2.6;  $p < 0.001$ ). These results are in agreement with a phenotypic study of 467 Brazilian *C. neoformans* isolates by Nishikawa et al. (2003), which showed serotype A (*C. neoformans*) associated with the Southeastern region (which is in the SM), and serotype B (*C. gattii*) associated with the NE region (which is in the NM) of Brazil.

*C. neoformans* is the most common agent of cryptococcosis worldwide, and it mainly affects AIDS patients. In Brazil, over 70% of AIDS patients live in the South and Southeast regions (Brito et al. 2001). These regions contain the largest cities of the country, and deforestation and anthropic actions are more evident in them (Lazéra et al. 2005, Pedroso et al. 2007). On the contrary, *C. gattii* affects mainly immunocompetent hosts and has a natural habitat predominantly related to wood decay in tropical and subtropical countries. The predominance of *C. gattii* as the main agent of cryptococcosis in the NM of Brazil is reinforced by the similar results found during analysis of the environmental isolates (OD 2.3;  $p < 0.001$ ).

With regard to the molecular types of the NM and SM of Brazil, no significant differences were observed regarding the occurrence of VNI. VGII clearly occurs endemically in the NM, where it is responsible for 89% of the *C. gattii* infections. In the SM, only 43% of the *C. gattii* infections are caused by VGII. Moreover, the majority of the VGII clinical isolates in RJ were obtained from patients coming from the NE region of Bra-

TABLE II

Logistic regression model of probability of VNI occurrence in clinical samples according to the host status ( $n = 291$ )

| Host status       | Relative Risk (95% CI) | p-value | Adjusted Relative Risk (95% CI) | p-value |
|-------------------|------------------------|---------|---------------------------------|---------|
| Immunocompromised | 2.18 (1.7-2.9)         | < 0.001 | 6.19 (3.0-13.0)                 | < 0.001 |
| Immunocompetent   | 1.00                   | -       | 1.00                            | -       |

CI: confidence interval.

TABLE III

Logistic regression model of probability of VGII occurrence in clinical samples with interactions between the predictors host status and macro region ( $n = 291$ )

| Characteristics            | Risk Relative (95% CI) | p-value | Adjusted Risk Relative (95% CI) | p-value |
|----------------------------|------------------------|---------|---------------------------------|---------|
| Host status                |                        |         |                                 |         |
| Immunocompetent            | 11.20 (6.8-18.5)       | < 0.001 | 11.71 (4.4-31.2)                | < 0.001 |
| Immunocompromised          | 1.00                   | -       | 1.00                            | -       |
| Macro region               |                        |         |                                 |         |
| Northern (NM)              | 16.0 (8.4-30.7)        | < 0.001 | 17.57 (5.2-59.6)                | < 0.001 |
| Southern (SM)              | 1.00                   | -       | 1.00                            | -       |
| Host status × Macro region |                        |         |                                 |         |
| Immunocompetent × NM       | -                      | -       | 0.14 (0.03-0.57)                | 0.006   |
| Immunocompetent × SM       | -                      | -       | 1.00                            | -       |
| Immunocompromised × NM     | -                      | -       | 1.00                            | -       |
| Immunocompromised × SM     | -                      | -       | 1.00                            | -       |

CI: confidence interval.

zil (Rozenbaum & Gonçalves 1994, MS Lazera, unpublished data) who went to the large cities of the South in search of better living conditions. This explanation may also account for the VGII clinical isolates obtained in other cities (e.g. São Paulo, the most important center of internal migration in Brazil). Considering the large

extent of inland migration, therefore, the molecular types of clinical origin of a certain region should be correlated with the molecular typing of the environmental isolates of that region. In the present study, 36 of the 37 *C. gattii* environmental isolates were isolated in the NM. All of these were VGII, which reinforces once again its predominance in that region. The only environmental *C. gattii* isolate obtained in the SM was molecular type VGI. However, the molecular type VGI was not detected among the clinical and environmental isolates from the NM, suggesting that this type may occur in higher latitudes of tropical or subtropical regions. Similar results were described by Escandón et al. (2006) in Colombia, where only one of 425 isolates of the *Cryptococcus* species complex was identified as VGI; the majority (99.2%) of the *C. gattii* isolates were of the molecular type VGII. Recent molecular typing studies in Brazil have shown the presence of VNI and VNII in clinical samples and VNI, VNIV, and VGI in environmental samples in the SM (i.e. states of SP and RS) (Abegg et al. 2006, Ribeiro et al. 2006, Matsumoto et al. 2007).

Studies of molecular polymorphisms in infective agents have led to a better understanding of those agents' epidemiology and may contribute to the evaluation of interventions and treatments. Martins et al. (2007) analyzed serial isolates from HIV patients using pulsed field gel electrophoresis and RAPD-PCR, and their findings suggested that patients may be infected by more than one isolate. Similarly, Almeida et al. (2007) used RAPD-PCR to analyze primarily Brazilian *C. neoformans* isolates. These authors observed a high correlation between a distinct genetic profile in serial samples and the tendency to become resistant to antifungal drugs. In the current study, the molecular polymorphism analysis showed a lower similarity rate (77%) among VGII than VNI isolates (87%). The VGII isolates may have a higher rate of mutation, which could produce a poorer response to antifungal therapy (Yee-Chun et al. 2000).

Mat alpha cells are more virulent than Mat a cells. As in the present study, these cells predominate in clinical and environmental samples worldwide. In the NM region, VGII Mat a was identified as agent of systemic cryptococcosis in five immunocompetent patients. These findings denote an uncommon picture of the pathogenesis of cryptococcosis and warrant further study to elucidate the impact of the mating locus in *C. gattii* infections. The finding of both mating types in Brazilian VGII isolates is of great interest in connection with the search for the possible origin of the recent outbreak of cryptococcosis on Vancouver Island British Columbia, Canada. In this case, all isolates of the causative agent were VGII Mat alpha strains (Kidd et al. 2004).

Because the VGII molecular type existed in Brazil long before the British Columbia outbreak and we have identified both mating types, Mat alpha and Mat a, geographically proximal to one another, we suggest the possibility of genetic recombination among those yeast populations in South America. The results of such recombination may spread in the environment as adapted polymorphic populations.




Fig. 3: phenogram of PCR-fingerprinting profiles obtained with the M13 primer from 87 Brazilian isolates. The isolates clustered into five major groups corresponding to the molecular types: VNI, VNII and VNIV (*C. neoformans*), and VGI and VGII (*C. gattii*). The Brazilian *C. neoformans* isolates generated 10 different bands pattern profiles, while the Brazilian *C. gattii* isolates formed 20 bands pattern profiles.

The first VGII strain (LMM 293) identified in Brazil was isolated in RJ in 1988 from a patient coming from the NM. Brazil is a large continental country with many different geographic and demographic patterns. In the northern region, the Amazon rainforest encompasses partially preserved wild areas surrounding urban cities or settlements. In the NE region, the central semi-arid area is covered by brushwood known as "caatinga". Despite these differences, our results showed the occurrence of *C. gattii* VGII in the environment of both regions. It behaved as a primary pathogen of human infection in native, normal hosts and primarily caused meningoencephalitis, attaining a prevalence of 20 to 30% in children and adolescents.

In accordance with the human infections by *C. gattii* VGII in the NM of Brazil, several genera of trees (e.g., *Cassia* sp., *Ficus* sp., *Guatarda* sp., *Erythrina* sp., and *Licania* sp.) can harbor this yeast in their hollows (Lazéra et al. 1998, 2000, Fortes et al. 2001). Clinical isolates are thus more likely to be found in deforestation areas, which are located mainly on the border of rainforests. A recent diagnosis (2006) of meningoencephalitis due to a VGII strain in a 5-year-old child (not included in the present analysis) who lived his entire life in RJ (SM) suggests that the VGII type may be spreading from the NM. It may be adapting to new areas in the SM due to anthropic activity and global climatic changes. It is also possible that this molecular type has long been present at a low density in the SM, thereby causing occasional human cases. Similarly, it has been suggested that *C. gattii* VGII has recently colonized the temperate region of Vancouver Island via unknown events and that forestry activities and the distribution of tree by-products may have facilitated the mobility of *C. gattii* through aerosolization and mechanical dispersal to non-endemic areas within the Pacific Northwest (Fraser et al. 2005, Kidd et al. 2007, Upton et al. 2007). This emphasizes the need for an active surveillance program of new human and animal infections by VGII strains in the SM.

It is very important to note that VGII is not a rare genotype of *C. gattii* in South America. In fact, it behaves as a primary fungal pathogen and causes endemic cryptococcosis in immunocompetent hosts in the northern macro region of Brazil, where it is particularly well-adapted to environmental biotypes associated with wood decay. Our findings suggest that this eco-epidemiological pattern of the VGII genotype in Brazil is not a recent event and has been recognized for at least the last 20 years.

## REFERENCES

- Abegg MA, Cella FL, Faganello J, Valente P, Schrank A, Vainstein MH 2006. *Cryptococcus neoformans* and *Cryptococcus gattii* isolated from the excreta of psittaciformes in a southern Brazilian zoological garden. *Mycopathologia* 161: 83-91.
- Boekhout T, Theelen B, Diaz M, Fell JW, Hop WC, Abeln EC, Dromer F, Meyer W 2001. Hybrid genotypes in the pathogenic yeast *Cryptococcus neoformans*. *Microbiology* 147: 891-907.
- Brito AM, Castilho EA, Szwarcwald CL 2001. AIDS e infecção pelo HIV no Brasil: uma epidemia multifacetada. *Rev Soc Bras Med Trop* 34: 207-217.
- Casali AK, Goulart L, Rosa e Silva LK, Ribeiro AM, Amaral AA, Alves SH, Schrank A, Meyer W, Vainstein MH 2003. Molecular typing of clinical and environmental *Cryptococcus neoformans* isolates in the Brazilian state Rio Grande do Sul. *FEMS Yeast Res* 3: 405-415.
- Chaturvedi S, Rodeghier B, Fan J, McClelland CM, Wickes BL, Chaturvedi V 2000. Direct PCR of *Cryptococcus neoformans* MATa and MATα pheromones to determine mating type, ploidy, and variety: a tool for epidemiological and molecular pathogenesis studies. *J Clin Microbiol* 38: 2007-2009.
- Correa MP, Oliveira EC, Duarte RR, Pardal PP, Oliveira FM, Severo LC 1999. Cryptococcosis in children in the State of Para, Brazil. *Rev Soc Bras Med Trop* 32: 505-508.
- Escandón P, Sanchez A, Martinez M, Meyer W, Castaneda E 2006. Molecular epidemiology of clinical and environmental isolates of the *Cryptococcus neoformans* species complex reveals a high genetic diversity and the presence of the molecular type VGII mating type a in Colombia. *FEMS Yeast Res* 6: 625-635.
- Fortes ST, Lazéra MS, Nishikawa MM, Macêdo RCL, Wanke B 2001. First isolation of *Cryptococcus neoformans* var. *gattii* from a native jungle tree in the Brazilian Amazon rainforest. *Mycosis* 44: 137-140.
- Fraser JA, Giles SS, Wenink EC, Geunes-Boyer SG, Wright JR, Diezmann S, Allen A, Stajich JE, Dietrich FS, Perfect JR, Heitman J 2005. Same-sex mating and the origin of the Vancouver Island *Cryptococcus gattii* outbreak. *Nature* 27: 1360-1364.
- Fraser JA, Subaran RL, Nichols CB, Heitman J 2003. Recapitulation of the sexual cycle of the primary fungal pathogen *Cryptococcus neoformans* var. *gattii*: Implications for an outbreak on Vancouver Island, Canada. *Eukaryot Cell* 2: 1036-1045.
- Halliday CL, Carter DA 2003. Clonal reproduction and limited dispersal in an environmental population of *Cryptococcus neoformans* var. *gattii* Isolates from Australia. *J Clin Microbiol* 41: 703-711.
- Igreja RP, Lazéra MS, Wanke B, Galhardo MC, Kidd SE, Meyer W 2004. Molecular epidemiology of *Cryptococcus neoformans* isolates from AIDS patients of the Brazilian city, Rio de Janeiro. *Med Mycol* 42: 229-238.
- Katsu M, Kidd S, Ando A, Moretti-Branchini ML, Mikami Y, Nishimura K, Meyer W 2004. The internal transcribed spacers and 5.8S rRNA gene show extensive diversity among isolates of the *Cryptococcus neoformans* species complex. *FEMS Yeast Res* 4: 377-388.
- Kidd SE, Bach PJ, Hingston AO, Mak S, Chow Y, MacDougall L, Kronstad JW, Bartlett KH 2007. *Cryptococcus gattii* dispersal mechanisms, British Columbia, Canada. *Emerg Infect Dis* 13: 51-57.
- Kidd SE, Hagen F, Tschärke RL, Huynh M, Bartlett KH, Fyfe M, Macdougall L, Boekhout T, Kwon-Chung KJ, Meyer W 2004. A rare genotype of *Cryptococcus gattii* caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). *Proc Natl Acad Sci USA* 101: 17258-17263.
- Kwon-Chung KJ, Bennett JE 1992. Cryptococcosis. In KJ Kwon-Chung, JE Bennett (eds.), *Medical Mycology*, Lea & Febiger, Philadelphia, p. 397-446.
- Kwon-Chung KJ, Boekhout T, Fell JW, Diaz M 2002. (1557) Proposal to conserve the name *Cryptococcus gattii* against *C. hondurians* and *C. bacillisporus* (Basidiomycota, Hymenomycetes, Tremellonycetidae). *Taxon* 51: 804-806.
- Latouche GN, Huynh M, Sorrell TC, Meyer W 2003. PCR-restriction fragment length polymorphism analysis of the phospholipase B (PLB1) gene for subtyping of *Cryptococcus neoformans* isolates. *Appl Environ Microbiol* 69: 2080-2086.

- Lazéra MS, Cavalcanti MAS, Londero AT, Trilles L, Nishikawa MM, Wanke B 2000. Possible primary ecological niche of *Cryptococcus neoformans*. *Med Mycol* 38: 379-383.
- Lazéra MS, Cavalcanti MAS, Trilles L, Nishikawa MM, Wanke B 1998. *Cryptococcus neoformans* var. *gattii* in a pottery tree hollow - evidence for a natural habitat related to decaying wood. *J Med Vet Mycol* 36: 119-122.
- Lazéra MS, Gutierrez-Galhardo MC, Cavalcanti MAS, Wanke B 2005. *Criptococose*. In: JR Coura (ed.), *Dinâmica das doenças infecciosas e parasitárias*, Guanabara Koogan, Rio de Janeiro, p. 1223-1236.
- Lin X, Heitman J 2006. The biology of the *Cryptococcus neoformans* species complex. *Annu Rev Microbiol* 60: 69-105.
- Litvintseva AP, Thakur R, Vilgalys R, Mitchell TG 2006. Multilocus sequence typing reveals three genetic subpopulations of *Cryptococcus neoformans* var. *grubii* (serotype A), including a unique population in Botswana. *Genetics* 172: 2223-2238.
- Martins MA, Pappalardo MCSM, Melhem MSC, Pereira-Chioccola VL 2007. Molecular diversity of serial *Cryptococcus neoformans* isolates from AIDS patients in the city of São Paulo, Brazil. *Mem Inst Oswaldo Cruz* 102: 777-784.
- Matsumoto MT, Fusco-Almeida AM, Baeza LC, Melhem MS, Medes-Giannini MJ 2007. Genotyping, serotyping and determination of mating-type of *Cryptococcus neoformans* clinical isolates from São Paulo State, Brazil. *Rev Inst Med Trop Sao Paulo* 49: 41-47.
- Meyer W, Castañeda A, Jackson S, Huynh M, Castañeda E, IberoAmerican Cryptococcal Study Group 2003. Molecular typing of IberoAmerican *Cryptococcus neoformans* isolates. *Emerg Infect Dis* 9: 189-195.
- Meyer W, Marszewska K, Amirmostofina M, Igreja RP, Hardtke C, Methling K, Viviani MA, Chindamporn A, Sukroongreung S, John MA, Ellis DH, Sorrell TC 1999. Molecular typing of global isolates of *Cryptococcus neoformans* var. *neoformans* by PCR-fingerprinting and RAPD. A pilot study to standardize techniques on which to base a detailed epidemiological survey. *Electrophoresis* 20: 1790-1799.
- Nishikawa MM, Lazera MS, Barbosa GG, Trilles L, Balassiano BR, Macedo RC, Bezerra CC, Pérez MA, Cardarelli P, Wanke B 2003. Serotyping of 467 *Cryptococcus neoformans* isolates from clinical and environmental sources in Brazil: analysis of host and regional patterns. *J Clin Microbiol* 41: 73-77.
- Pedroso RS, Ferreira JC, Candido RC 2007. The isolation and characterization of virulence factors of *Cryptococcus* spp. from saprophytic sources in the city of Ribeirão Preto, São Paulo, Brazil. *Microbiol Res*, in press.
- Ribeiro AM, Silva LKR, Schrank IS, Schrank A, Meyer W, Vainstein MH 2006. Isolation of *Cryptococcus neoformans* var. *neoformans* serotype D from Eucalypts in South Brazil. *Med Mycol* 44: 707-713.
- Rozenbaum R, Gonçalves AJ 1994. Clinical epidemiological study of 171 cases of cryptococcosis. *Clin Infect Dis* 18: 369-380.
- Trilles L, Lazéra MS, Wanke B, Theelen B, Boekhout T 2003. Genetic characterization of environmental isolates of the *Cryptococcus neoformans* species complex from Brazil. *Med Mycol* 41: 383-390.
- Upton A, Fraser JA, Kidd SE, Bretz C, Bartlett KH, Heitman J, Marr KA 2007. First contemporary case of human infection with *Cryptococcus gattii* in Puget Sound: evidence for spread of the Vancouver Island outbreak. *J Clin Microbiol* 45: 3086-3088.
- Yee-Chun C, Shan-Chwen C, Chiang-Ching S, Chien-Ching H, Kwen-Tay L, Yueh-Shya P, Wei-Chuan H 2000. Clinical features and in vitro susceptibilities of the two varieties of *Cryptococcus neoformans* in Taiwan. *Diagn Microbiol Infect Dis* 36: 175-183.



Supplementary data  
List of the Brazilian isolates and their respective data included in the analysis

| LA code | Original codes/others | Serotype | Molecular Type | AFLP Type <sup>a</sup> | Mating Type | State | Source   | Host Factors | Reference                   |
|---------|-----------------------|----------|----------------|------------------------|-------------|-------|----------|--------------|-----------------------------|
| LA 70   | HEC 4744, LMM 210     | A        | VNI            |                        | alpha       | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 71   | HEC 4759, LMM 207     | A        | VNI            |                        | alpha       | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 88   | HEC 3385, LMM 275     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 89   | HEC 3393, LMM 276     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 90   | HEC 3451, LMM 277     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 64   | HEC 4262, LMM 226     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 65   | HEC 4407, LMM 221     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 66   | HEC 4418, LMM 220     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 67   | HEC 4436, LMM 219     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 68   | HEC 4532, LMM 217     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 69   | HEC 4576, LMM 216     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 72   | HEC 4859, LMM 205     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 97   | HEC 5988, LMM 656     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 98   | HEC 6047, LMM 126     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 99   | HEC 6196, LMM 117     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 91   | HEC 7389, LMM 92      | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 92   | HEC 7576, LMM 663     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 94   | HEC 7835, LMM 658     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 95   | HEC 7836, LMM 657     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 96   | HEC 8104, LMM 69      | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 93   | HEC 8462, LMM 59      | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 100  | HEC 10720, LMM 33     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 82   | HEC 10724, LMM 32     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 83   | HEC 10726, LMM 31     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 85   | HEC 11116, LMM 20     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 86   | HEC 11127, LMM 19     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 87   | HEC 11376, LMM 13     | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 101  | HEC 12284, LMM 228    | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 75   | HEC 13245, LMM 529    | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 76   | HEC 13247, LMM 617    | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 77   | HEC 13249, LMM 673    | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 78   | HEC 13262, LMM 619    | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 79   | HEC 13341             | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 73   | HEC 13670, LMM 550    | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 74   | HEC 13722, LMM 555    | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
|         | HEC 13912             | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 81   | HEC 14047, LMM 674    | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 108  | HUCFF B-19/97         | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |
| LA 141  | HUCFF B-30/97         | A        | VNI            |                        | not typed   | RJ    | clinical | HIV+         | Med Mycol 2004; 42: 229-238 |



| LA code | Original codes/others | Serotype  | Molecular Type | AFLP Type <sup>a</sup> | Mating Type | State | Source        | Host Factors | Reference                                |
|---------|-----------------------|-----------|----------------|------------------------|-------------|-------|---------------|--------------|------------------------------------------|
| LA 109  | HUCFF B-49/97         | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 143  | HUCFF B-229/96        | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 119  | HUCFF B-294/97        | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 105  | HUCFF B-444/94        | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 123  | HUCFF B-493/96        | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 131  | HUCFF B-545/96        | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 145  | HUCFF B-573/96        | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 133  | HUCFF B-605/97        | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 135  | HUCFF B-683/96        | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 139  | HUCFF B-960/96        | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 118  | HUCFF B-1295/96       | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 110  | HUCFF B-1616/93       | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 137  | HUCFF B-2128/96       | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 106  | HUCFF B-2202/96       | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 107  | HUCFF B-2218/96       | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 140  | HUCFF H-06/97         | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 113  | HUCFF H-10/97         | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 115  | HUCFF H-88/96 (15/2)  | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 142  | HUCFF H-88/96 (26/6)  | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 128  | HUCFF H-106/97        | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 112  | HUCFF H-120/96        | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 104  | HUCFF H-137/96        | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 130  | HUCFF H-146/97        | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 132  | HUCFF H-154/96        | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 134  | HUCFF H-165/96        | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 111  | HUCFF H-195/97        | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 136  | HUCFF H-243/96        | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 138  | HUCFF H-293/96        | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 147  | HUCFF H-305/96        | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 148  | HUCFF H-377/96        | A         | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 419  | Hamdan F2'1           | A         | VNI            | 1                      | alpha       | MG    | environmental | N/A          | <i>Microbiology</i> 2001; 147: 891-907   |
| LA 420  | Hamdan I3'1           | A         | VNI            | 1                      | alpha       | MG    | environmental | N/A          | <i>Microbiology</i> 2001; 147: 891-907   |
| LA 421  |                       | not typed | VNI            |                        | alpha       | RJ    | environmental | N/A          | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 422  |                       | not typed | VNI            |                        | alpha       | RJ    | environmental | N/A          | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 147  | RJ 62, LMM 381        | A         | VNI            | 1                      | alpha       | RJ    | environmental | N/A          | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 148  | RJ 63, LMM 380        | A         | VNI            | 1                      | not typed   | RJ    | environmental | N/A          | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 102  | HUCFF B-64/97         | A         | VNII           |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |

L

| LA code | Original codes/others | Serotype  | Molecular Type | AFLP Type <sup>a</sup> | Mating Type | State | Source        | Host Factors | Reference                                |
|---------|-----------------------|-----------|----------------|------------------------|-------------|-------|---------------|--------------|------------------------------------------|
| LA 103  | HUCFF B-175/97        | A         | VNII           |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 127  | HUCFF B-308/96        | A         | VNII           |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 117  | HUCFF B-583/97        | A         | VNII           |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 116  | HUCFF B-1267/96       | A         | VNII           |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 125  | HUCFF B-1396/95       | A         | VNII           |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 120  | HUCFF B-1773/94       | A         | VNII           |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 126  | HUCFF H-91/96         | A         | VNII           |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 121  | HUCFF H-97/96         | A         | VNII           |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 124  | HUCFF H-318/95        | A         | VNII           | 1A                     | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
|         | Hamdan C3-1           | A         | VNII           |                        | alpha       | RJ    | environmental | N/A          | <i>FEMS Yeast Res</i> 2004; 4: 377-388;  |
| LA 146  | RJ 24, LMM 385        | A         | VNII           | 1A                     | alpha       | RJ    | environmental | N/A          | <i>Microbiology</i> 2001; 147: 891-907   |
| LA 149  | RJ 64, LMM 379        | A         | VNII           |                        | not typed   | RJ    | environmental | N/A          | <i>Med Mycol</i> 2004; 42: 229-238;      |
| LA 150  | HEC 3724, LMM 456     | not typed | VGI            |                        | not typed   | RJ    | clinical      | unknown      | <i>Microbiology</i> 2001; 147: 891-907   |
| LA 84   | HEC 11102, LMM 21     | not typed | VGII           | 6                      | alpha       | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 55   | HEC 11241, LMM 16     | not typed | VGII           |                        | not typed   | SP    | clinical      | HIV+         | <i>FEMS Yeast Res</i> 2004; 4: 377-388;  |
| LA 57   | LMM 417               | B         | VGII           | 6                      | not typed   | PI    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238       |
| LA 59   | LMM 513               | A         | VNI            |                        | not typed   | PI    | clinical      | HIV-         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 61   | LMM 557               | not typed | VGII           |                        | not typed   | PI    | clinical      | HIV-         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 346  | 481(5)                | A         | VNI            |                        | not typed   | PI    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 347  | 482(5)                | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 348  | 540(9)                | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 349  | 541(9)                | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 350  | 14(9)                 | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 351  | 13(11)                | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 352  | 49(11)                | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 353  | 98(17)                | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 354  | 14(17)                | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 355  | 221(23)               | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 356  | 18(23)                | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 357  | 222(24)               | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 358  | 65(24)                | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 359  | 62(27)                | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 360  | 66(27)                | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 361  | 67(27)                | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 363  | 1342                  | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 364  | 1755                  | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 365  | 1920                  | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 366  | 2177                  | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |



| LA code | Original codes/others | Serotype  | Molecular Type | AFLP Type <sup>a</sup> | Mating Type | State | Source        | Host Factors | Reference                                |
|---------|-----------------------|-----------|----------------|------------------------|-------------|-------|---------------|--------------|------------------------------------------|
| LA 362  | BirdI                 | B         | VGII           |                        | not typed   | SP    | veterinary    | N/A          | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 326  | LCS-534               | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 328  | GFR-1505              | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 329  | AFG-34                | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 330  | AFG-14                | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 331  | CMS-1226              | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 332  | AFG-25/00             | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 333  | PRL-1133              | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 334  | JCJ-1157              | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 335  | MAAC-1866             | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 336  | VPD-25                | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 337  | AFG-09/00             | not typed | VGII           |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 338  | AFG-15/00             | not typed | VGII           |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 339  | LCS-394               | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 340  | IFOC-1446             | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 341  | MO-438                | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 342  | KSO-948               | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 343  | CSC-1016              | A         | VNII           |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 344  | MDS-949               | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 345  | MEM-1064              | A         | VNI            |                        | not typed   | SP    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 755  | HC2                   | A         | VNI            |                        | not typed   | RS    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 756  | HC3                   | A         | VNII           |                        | not typed   | RS    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 757  | HC4                   | A         | VNI            |                        | not typed   | RS    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 758  | HC6                   | A         | VNI            |                        | not typed   | RS    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 759  | HC8                   | A         | VNI            |                        | not typed   | RS    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 760  | HC9                   | A         | VNI            |                        | not typed   | RS    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 761  | HC10                  | A         | VNI            |                        | not typed   | RS    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 762  | HC11                  | A         | VNI            |                        | not typed   | RS    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 763  | HC13                  | A         | VNI            |                        | not typed   | RS    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 764  | HC14                  | A         | VNI            |                        | not typed   | RS    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 765  | HC15                  | A         | VNI            |                        | not typed   | RS    | clinical      | HIV+         | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 44   | LMM 414               | B         | VGII           |                        | not typed   | PI    | environmental | N/A          | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 45   | LMM 415               | B         | VGII           |                        | not typed   | PI    | environmental | N/A          | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 47   | LMM 434               | B         | VGII           |                        | not typed   | PI    | environmental | N/A          | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 52   | LMM 561               | A         | VNI            |                        | not typed   | PI    | environmental | N/A          | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
| LA 54   | LMM 564               | A         | VNI            |                        | not typed   | PI    | environmental | N/A          | <i>Emerg Infect Dis</i> 2003; 9: 189-195 |
|         | LMM 9                 | AD        | VNII           | 1A                     | alpha       | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2003; 41: 383-390       |
|         | LMM 23                | B         | VGII           | 6                      | alpha       | PI    | clinical      | HIV-         | <i>Med Mycol</i> 2003; 41: 383-390       |
|         | LMM 29                | B         | VGII           | 6                      | alpha       | PI    | clinical      | HIV-         | <i>Med Mycol</i> 2003; 41: 383-390       |
|         | LMM 34                | A         | VNII           | 1A                     | alpha       | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2003; 41: 383-390       |
|         | LMM 379               | A         | VNII           | 1A                     | alpha       | RJ    | environmental | N/A          | <i>Med Mycol</i> 2003; 41: 383-390       |
|         | LMM 388               | D         | VNIII          | 3                      | not typed   | RJ    | environmental | N/A          | <i>Med Mycol</i> 2003; 41: 383-390       |

L→

| LA code    | Original codes/others | Serotype | Molecular Type | AFLP Type <sup>a</sup> | Mating Type | State | Source        | Host Factors | Reference                   |
|------------|-----------------------|----------|----------------|------------------------|-------------|-------|---------------|--------------|-----------------------------|
| LMM 414    |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 484.1  |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 484.2  |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 484.3  |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 489    |                       | A        | VNI            | 1                      | alpha       | RJ    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 495    |                       | A        | VNI            | 1                      | alpha       | RJ    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 496    |                       | A        | VNI            | 1                      | alpha       | RJ    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 498    |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 526    |                       | A        | VNI            | 1                      | alpha       | AM    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 527    |                       | A        | VNI            | 1                      | alpha       | AM    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 544.1  |                       | A        | VNI            | 1                      | alpha       | RJ    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 544.2  |                       | A        | VNI            | 1                      | alpha       | RJ    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 547.1  |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 547.2  |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 547.3  |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 547.4  |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 547.5  |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 547.6  |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 547.7  |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 547.9  |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 547.10 |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 547.11 |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 547.13 |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 547.14 |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 547.15 |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 547.16 |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 547.17 |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 547.18 |                       | D        | VNIV           | 2                      | a           | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 547.19 |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 561.5  |                       | A        | VNI            | 1                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 561.6  |                       | A        | VNI            | 1                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 562.1  |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 562.2  |                       | A        | VNI            | 1                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 562.3  |                       | A        | VNI            | 1                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 562.4  |                       | A        | VNI            | 1                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 562.5  |                       | A        | VNI            | 1                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 562.6  |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 562.7  |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 562.9  |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 562.10 |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 562.11 |                       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |
| LMM 562.12 |                       | A        | VNI            | 1                      | alpha       | PI    | environmental | N/A          | Med Mycol 2003; 41: 383-390 |



| LA code | Original codes/others | Serotype | Molecular Type | AFLP Type <sup>a</sup> | Mating Type | State | Source        | Host Factors | Reference                              |
|---------|-----------------------|----------|----------------|------------------------|-------------|-------|---------------|--------------|----------------------------------------|
|         | LMM 562.13            | A        | VNI            | 1                      | alpha       | PI    | environmental | N/A          | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 562.15            | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 562.16            | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 564.9             | A        | VNI            | 1                      | alpha       | PI    | environmental | N/A          | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 564.10            | A        | VNI            | 1                      | alpha       | PI    | environmental | N/A          | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 564.11            | A        | VNI            | 1                      | alpha       | PI    | environmental | N/A          | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 564.14            | A        | VNI            | 1                      | alpha       | PI    | environmental | N/A          | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 564.17            | A        | VNI            | 1                      | alpha       | PI    | environmental | N/A          | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 564.19            | A        | VNI            | 1                      | alpha       | PI    | environmental | N/A          | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 564.21            | A        | VNI            | 1                      | alpha       | PI    | environmental | N/A          | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 564.26            | A        | VNI            | 1                      | alpha       | PI    | environmental | N/A          | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 564.27            | A        | VNI            | 1                      | alpha       | PI    | environmental | N/A          | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 655               | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 706               | A        | VNI            | 1                      | alpha       | RS    | clinical      | unknown      | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 715               | A        | VNI            | 1                      | alpha       | RS    | clinical      | unknown      | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 736               | A        | VNI            | 1                      | alpha       | MS    | clinical      | HIV+         | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 739               | A        | VNI            | 1                      | alpha       | MS    | clinical      | HIV+         | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 744               | A        | VNI            | 1                      | alpha       | MS    | clinical      | HIV+         | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 866               | B        | VGII           | 6                      | alpha       | RR    | clinical      | HIV-         | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 876.1             | D        | VNIV           | 2                      | a           | PI    | environmental | N/A          | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 876.2             | D        | VNIV           | 2                      | a           | PI    | environmental | N/A          | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 878.3             | A        | VNI            | 1                      | alpha       | PI    | environmental | N/A          | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 878.4             | A        | VNI            | 1                      | alpha       | PI    | environmental | N/A          | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 916               | C        | VGIII          | 5                      | alpha       | RJ    | clinical      | HIV-         | <i>Med Mycol</i> 2003; 41: 383-390     |
|         | LMM 421               | A        | VNI            | 1                      | not typed   | RJ    | environmental | N/A          | <i>Microbiology</i> 2001; 147: 891-907 |
|         | LMM 422               | A        | VNI            | 1                      | not typed   | RJ    | environmental | N/A          | <i>Microbiology</i> 2001; 147: 891-907 |
|         | Hamdan 214-L          | A        | VNII           | 1A                     | not typed   | MG    | clinical      | HIV+         | <i>Microbiology</i> 2001; 147: 891-907 |
|         | Hamdan 299            | A        | VNII           | 1A                     | not typed   | MG    | clinical      | HIV+         | <i>Microbiology</i> 2001; 147: 891-907 |
|         | Hamdan 822-B          | A        | VNI            | 1                      | not typed   | MG    | clinical      | HIV+         | <i>Microbiology</i> 2001; 147: 891-907 |
|         | Hamdan C31            | A        | VNII           | 1A                     | not typed   | MG    | clinical      | HIV+         | <i>Microbiology</i> 2001; 147: 891-907 |
|         | Hamdan MCP-2          | A        | VNII           | 1A                     | not typed   | MG    | environmental | N/A          | <i>Microbiology</i> 2001; 147: 891-907 |
|         | Hamdan WP             | A        | VNI            | 1                      | not typed   | MG    | clinical      | HIV+         | <i>Microbiology</i> 2001; 147: 891-907 |
|         | RV63642               | A        | VNI            | 1                      | not typed   | MG    | clinical      | HIV+         | <i>Microbiology</i> 2001; 147: 891-907 |
|         | RV66095               | B        | VGI            | 4A                     | not typed   | PR    | clinical      | HIV-         | <i>Microbiology</i> 2001; 147: 891-907 |
|         | IFM 5880, UFPR 2262   | B        | VGI            |                        | not typed   | PR    | clinical      | unknown      | <i>FEMS Yeast Res</i> 2004; 4: 377-388 |
|         | IFM 48219, A465       | B        | VGI            |                        | not typed   | PR    | clinical      | unknown      | <i>FEMS Yeast Res</i> 2004; 4: 377-388 |
|         | IFM 5883, UFPR 2527   | B        | VGII           |                        | not typed   | PE    | clinical      | unknown      | <i>FEMS Yeast Res</i> 2004; 4: 377-388 |
|         | IFM 48213, FT 84      | B        | VGII           |                        | not typed   | PR    | clinical      | unknown      | <i>FEMS Yeast Res</i> 2004; 4: 377-388 |
|         | IFM 48216, FT 119     | B        | VGII           |                        | not typed   | PR    | clinical      | unknown      | <i>FEMS Yeast Res</i> 2004; 4: 377-388 |
|         | IFM 48221, A 288      | B        | VGII           |                        | not typed   | MG    | clinical      | unknown      | <i>FEMS Yeast Res</i> 2004; 4: 377-388 |
|         | IFM 48297, FT 130     | B        | VGII           |                        | not typed   | PR    | clinical      | unknown      | <i>FEMS Yeast Res</i> 2004; 4: 377-388 |
|         | CN011                 | B        | VGII           |                        | not typed   | SP    | clinical      | unknown      | <i>FEMS Yeast Res</i> 2004; 4: 377-388 |

L→

| LA code | Original codes/others | Serotype | Molecular Type | AFLP Type <sup>a</sup> | Mating Type | State | Source   | Host Factors | Reference                       |
|---------|-----------------------|----------|----------------|------------------------|-------------|-------|----------|--------------|---------------------------------|
|         | CN015                 | B        | VGII           |                        | not typed   | SP    | clinical | unknown      | FEMS Yeast Res 2004; 4: 377-388 |
|         | CN025                 | B        | VGII           |                        | not typed   | SP    | clinical | unknown      | FEMS Yeast Res 2004; 4: 377-388 |
|         | IFM 5875, UFPR-D1     | C        | VGIII          |                        | not typed   | PE    | clinical | unknown      | FEMS Yeast Res 2004; 4: 377-388 |
|         | IFM 5882, UFPR 2526   | C        | VGIII          |                        | not typed   | PE    | clinical | unknown      | FEMS Yeast Res 2004; 4: 377-388 |
|         | IFM 5884, UFPR 2528-1 | B        | VGIII          |                        | not typed   | PE    | clinical | unknown      | FEMS Yeast Res 2004; 4: 377-388 |
|         | IFM 5885, UFPR 2528-2 | B        | VGIII          |                        | not typed   | PE    | clinical | unknown      | FEMS Yeast Res 2004; 4: 377-388 |
| LA 55   | C1                    | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| LA 56   | C2                    | B        | VGIII          |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| LA 57   | C3                    | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| LA 58   | C4                    | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| LA 59   | C5                    | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| LA 60   | C6                    | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| LA 61   | C7                    | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| LA 62   | C8                    | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| LA 63   | C9                    | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C10                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C11                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C12                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C13                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C14                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C15                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C16                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C17                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C18                   | A        | VNI            |                        | a/alpha     | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C19                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C20                   | B        | VGIII          |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C21                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C22                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C23                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C24                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C26                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C27                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C28                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C29                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C30                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C31                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C32                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C33                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C34                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C35                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C36                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
|         | C37                   | A        | VNI            |                        | alpha       | RS    | clinical | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |



| L/A code | Original codes/others | Serotype | Molecular Type | AFLP Type <sup>a</sup> | Mating Type | State | Source   | Host Factors         | Reference                              |
|----------|-----------------------|----------|----------------|------------------------|-------------|-------|----------|----------------------|----------------------------------------|
| C38      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C39      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C40      |                       | B        | VGIII          |                        | alpha       | RS    | clinical | unknown              | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C41      |                       | B        | VGIII          |                        | alpha       | RS    | clinical | HIV-                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C42      |                       | B        | VGIII          |                        | alpha       | RS    | clinical | Tumor                | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C43      |                       | B        | VGIII          |                        | alpha       | RS    | clinical | Polio, toxoplasmosis | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C44      |                       | B        | VGIII          |                        | alpha       | RS    | clinical | HIV-                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C45      |                       | B        | VGIII          |                        | alpha       | RS    | clinical | Corticosteroid       | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C46      |                       | B        | VGIII          |                        | alpha       | RS    | clinical | HIV-                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C47      |                       | B        | VGIII          |                        | alpha       | RS    | clinical | unknown              | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C48      |                       | B        | VGIII          |                        | alpha       | RS    | clinical | HIV-                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C49      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C50      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C51      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C52      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C53      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C54      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C55      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C56      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C57      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C58      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C59      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C60      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C61      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C62      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C63      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C64      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C65      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C66      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C67      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C68      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C69      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C70      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C71      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C72      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C73      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C74      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C75      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C76      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C77      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C78      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| C79      |                       | A        | VNI            |                        | alpha       | RS    | clinical | HIV+                 | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |

L→



| LA code | Original codes/others | Serotype | Molecular Type | AFLP Type <sup>a</sup> | Mating Type | State | Source        | Host Factors | Reference                       |
|---------|-----------------------|----------|----------------|------------------------|-------------|-------|---------------|--------------|---------------------------------|
| C80     |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C81     |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C82     |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C83     |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C84     |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C85     |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C86     |                       | A        | VNI            |                        | alpha       | RS    | clinical      | unknown      | FEMS Yeast Res 2003; 3: 405-415 |
| C87     |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C88     |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C89     |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C90     |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C91     |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C92     |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C93     |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C94     |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C95     |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C96     |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C97     |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C98     |                       | A        | VNI            |                        | alpha       | RS    | clinical      | unknown      | FEMS Yeast Res 2003; 3: 405-415 |
| C99     |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C100    |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C101    |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C102    |                       | A        | VNI            |                        | alpha       | RS    | clinical      | unknown      | FEMS Yeast Res 2003; 3: 405-415 |
| C103    |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C104    |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| C105    |                       | A        | VNI            |                        | alpha       | RS    | clinical      | HIV+         | FEMS Yeast Res 2003; 3: 405-415 |
| LA 44   |                       | A        | VNI            |                        | alpha       | RS    | environmental | N/A          | FEMS Yeast Res 2003; 3: 405-415 |
| LA 45   |                       | A        | VNI            |                        | alpha       | RS    | environmental | N/A          | FEMS Yeast Res 2003; 3: 405-415 |
| LA 46   |                       | A        | VNI            |                        | alpha       | RS    | environmental | N/A          | FEMS Yeast Res 2003; 3: 405-415 |
| LA 47   |                       | A        | VNI            |                        | alpha       | RS    | environmental | N/A          | FEMS Yeast Res 2003; 3: 405-415 |
| LA 48   |                       | A        | VNI            |                        | alpha       | RS    | environmental | N/A          | FEMS Yeast Res 2003; 3: 405-415 |
| LA 49   |                       | A        | VNI            |                        | alpha       | RS    | environmental | N/A          | FEMS Yeast Res 2003; 3: 405-415 |
| LA 50   |                       | A        | VNI            |                        | alpha       | RS    | environmental | N/A          | FEMS Yeast Res 2003; 3: 405-415 |
| LA 51   |                       | A        | VNI            |                        | alpha       | RS    | environmental | N/A          | FEMS Yeast Res 2003; 3: 405-415 |
| LA 52   |                       | A        | VNI            |                        | alpha       | RS    | environmental | N/A          | FEMS Yeast Res 2003; 3: 405-415 |
| LA 53   |                       | A        | VNI            |                        | alpha       | RS    | environmental | N/A          | FEMS Yeast Res 2003; 3: 405-415 |
| LA 54   |                       | A        | VNI            |                        | alpha       | RS    | environmental | N/A          | FEMS Yeast Res 2003; 3: 405-415 |
| LA 337  |                       | D        | VNIV           |                        | alpha       | RS    | environmental | N/A          | FEMS Yeast Res 2003; 3: 405-415 |
| LA 338  |                       | D        | VNIV           |                        | alpha       | RS    | environmental | N/A          | FEMS Yeast Res 2003; 3: 405-415 |
| LA 339  |                       | D        | VNIV           |                        | alpha       | RS    | environmental | N/A          | FEMS Yeast Res 2003; 3: 405-415 |
| LA 340  |                       | D        | VNIV           |                        | alpha       | RS    | environmental | N/A          | FEMS Yeast Res 2003; 3: 405-415 |
| LA 341  |                       | D        | VNIV           |                        | alpha       | RS    | environmental | N/A          | FEMS Yeast Res 2003; 3: 405-415 |



| LA code | Original codes/others | Serotype | Molecular Type | AFLP Type <sup>a</sup> | Mating Type | State | Source        | Host Factors | Reference                              |
|---------|-----------------------|----------|----------------|------------------------|-------------|-------|---------------|--------------|----------------------------------------|
| LA 362  | E17                   | D        | VNIV           |                        | alpha       | RS    | environmental | N/A          | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| LA 343  | E18                   | D        | VNIV           |                        | alpha       | RS    | environmental | N/A          | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| LA 344  | E19                   | D        | VNIV           |                        | alpha       | RS    | environmental | N/A          | <i>FEMS Yeast Res</i> 2003; 3: 405-415 |
| LA 129  | HUCFF B-352/96        | A        | VNI            |                        | not typed   | RJ    | clinical      | HIV+         | <i>Med Mycol</i> 2004; 42: 229-238     |
|         | LMM 201               | B        | VGI            |                        | alpha       | RJ    | clinical      | unknown      |                                        |
|         | LMM 202               | B        | VGI            |                        |             | RJ    | clinical      | HIV-         |                                        |
|         | LMM 236               | AD       | VNI            | 1                      | alpha       | PI    | clinical      | HIV-         |                                        |
|         | LMM 244               | B        | VGI            |                        | alpha       | RJ    | clinical      | unknown      |                                        |
|         | LMM 249               |          | VNI            |                        |             | RJ    | clinical      | HIV+         |                                        |
|         | LMM 254               | A        | VNI            |                        | alpha       | RJ    | clinical      | HIV-         |                                        |
|         | LMM 260               | BC       | VGII           | 6                      | alpha       | RJ    | clinical      | unknown      |                                        |
|         | LMM 261               | B        | VGII           | 6                      | a           | RJ    | clinical      | HIV-         |                                        |
|         | LMM 265               | B        | VGII           |                        | alpha       | RJ    | clinical      | HIV+         |                                        |
|         | LMM 266               | B        | VGII           |                        | alpha       | RJ    | clinical      | HIV-         |                                        |
|         | LMM 272               | B        | VGI            |                        | alpha       | RJ    | clinical      | HIV-         |                                        |
|         | LMM 293               | B        | VGII           |                        | alpha       | RJ    | clinical      | HIV-         |                                        |
|         | LMM 296               |          | VNI            |                        | alpha       | RJ    | clinical      | HIV+         |                                        |
|         | LMM 319               | A        | VNI            |                        | alpha       | RJ    | clinical      | HIV-         |                                        |
|         | LMM 326               | B        | VGI            |                        | alpha       | RJ    | clinical      | unknown      |                                        |
|         | LMM 330               | B        | VGI            |                        | alpha       | RJ    | clinical      | HIV-         |                                        |
|         | LMM 347               | B        | VGI            |                        | alpha       | RJ    | clinical      | unknown      |                                        |
|         | LMM 353               | B        | VGI            |                        | alpha       | RJ    | clinical      | unknown      |                                        |
|         | LMM 355               | AD       | VNI            |                        | alpha       | RJ    | clinical      | HIV-         |                                        |
|         | LMM 356               | A        | VNI            |                        | alpha       | RJ    | clinical      | HIV+         |                                        |
|         | LMM 359               | B        | VGI            |                        | alpha       | RJ    | clinical      | unknown      |                                        |
|         | LMM 362               | B        | VGI            |                        | alpha       | RJ    | clinical      | unknown      |                                        |
|         | LMM 370               | A        | VNI            |                        | alpha       | RJ    | clinical      | unknown      |                                        |
|         | LMM 384               | B        | VGI            | 4                      | alpha       | RJ    | environmental | HIV+         |                                        |
|         | LMM 399               | B        | VGII           |                        | alpha       | RJ    | clinical      | N/A          |                                        |
|         | LMM 435               |          | VNI            |                        | alpha       | RJ    | clinical      | unknown      |                                        |
|         | LMM 480               |          | VNI            |                        | alpha       | RJ    | clinical      | HIV+         |                                        |
|         | LMM 498               | B        | VGII           |                        | alpha       | PI    | clinical      | HIV+         |                                        |
|         | LMM 504               |          | VGII           | 6                      | a           | PI    | environmental | N/A          |                                        |
|         | LMM 547.8             | A        | VNI            |                        | alpha       | PI    | clinical      | unknown      |                                        |
|         | LMM 547.18.2          | D        | VNIV           |                        | alpha       | PI    | environmental | N/A          |                                        |
|         | LMM 547.18.13A1       | D        | VNIV           | 2                      | a           | PI    | environmental | N/A          |                                        |
|         | LMM 547.18.13A3       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          |                                        |
|         | LMM 547.18.13B1       | B        | VGII           | 6                      | alpha       | PI    | environmental | N/A          |                                        |
|         | LMM 566               |          | VGII           | 6                      | alpha       | PI    | clinical      | HIV-         |                                        |
|         | LMM 567               | B        | VGII           | 6                      | alpha       | PI    | clinical      | HIV-         |                                        |
|         | LMM 574               |          | VGII           | 6                      | alpha       | PI    | clinical      | unknown      |                                        |
|         | LMM 576               | B        | VGII           |                        | alpha       | PI    | clinical      | unknown      |                                        |

L→

| LA code     | Original codes/others | Serotype | Molecular Type | AFLP Type <sup>a</sup> | Mating Type        | State | Source     | Host Factors | Reference |
|-------------|-----------------------|----------|----------------|------------------------|--------------------|-------|------------|--------------|-----------|
| LMM 624     |                       |          | VGII           |                        | alpha              | AM    | clinical   | HIV-         |           |
| LMM 631     |                       | B        | VGII           |                        | alpha              | BA    | clinical   | HIV-         |           |
| LMM 633     |                       | B        | VGII           |                        | alpha <sup>a</sup> | BA    | clinical   | HIV-         |           |
| LMM 634     |                       | B        | VGII           |                        | alpha              | BA    | clinical   | HIV-         |           |
| LMM 638     |                       | B        | VGII           |                        | alpha              | BA    | clinical   | HIV+         |           |
| LMM 716     |                       | A        | VNI            |                        | alpha              | AM    | clinical   | HIV+         |           |
| LMM 718     |                       | B        | VGII           |                        | alpha              | AM    | clinical   | HIV-         |           |
| LMM 722     |                       | B        | VGII           |                        | alpha              | AM    | clinical   | HIV-         |           |
| LMM 723     |                       | A        | VNI            |                        | alpha              | AM    | clinical   | HIV-         |           |
| LMM 724     |                       | B        | VGII           |                        | alpha              | AM    | clinical   | HIV-         |           |
| LMM 727     |                       | B        | VGII           |                        | alpha              | PI    | veterinary | N/A          |           |
| LMM 789     |                       |          | VGII           |                        | alpha              | RJ    | clinical   | HIV-         |           |
| LMM 791     |                       | B        | VGII           |                        | alpha <sup>a</sup> | PI    | clinical   | HIV-         |           |
| LMM 817     |                       | B        | VGII           |                        | alpha              | BA    | clinical   | unknown      |           |
| LMM 818     |                       | B        | VGII           |                        | alpha              | BA    | clinical   | unknown      |           |
| LMM 819     |                       | B        | VGII           |                        | alpha              | BA    | clinical   | unknown      |           |
| LMM 832     |                       | B        | VGII           |                        | alpha              | MS    | clinical   | HIV-         |           |
| LMM 843     |                       | B        | VGII           |                        | alpha              | BA    | clinical   | unknown      |           |
| LMM 855     |                       | B        | VGII           |                        | alpha              | RR    | clinical   | HIV-         |           |
| LMM 860     |                       | B        | VGII           | 6                      | alpha              | RR    | clinical   | HIV-         |           |
| LMM 892     |                       | B        | VGII           | 6                      | alpha              | RR    | clinical   | HIV-         |           |
| LMM 893     |                       | B        | VGII           | 6                      | alpha              | MS    | clinical   | HIV+         |           |
| LMM 900     |                       | B        | VGII           |                        |                    | MS    | clinical   | HIV+         |           |
| LMM 912     |                       | B        | VGII           |                        |                    | MS    | clinical   | HIV-         |           |
| LMM 920.7.1 |                       | B        | VGII           | 6                      | alpha              | MS    | clinical   | HIV-         |           |
| LMM 1003    |                       | BC       | VGII           | 6                      |                    | PI    | clinical   | unknown      |           |
| LMM 1029    |                       | A        | VNI            |                        |                    | PI    | clinical   | unknown      |           |
| LMM 1030    |                       | B        | VGII           |                        |                    | AM    | clinical   | HIV-         |           |
| LMM 1031    |                       | A        | VNI            |                        |                    | AM    | clinical   | HIV-         |           |
| LMM 1035    |                       | B        | VGII           |                        |                    | AM    | clinical   | HIV+         |           |
| LMM 1072    |                       | A        | VNI            |                        |                    | AM    | clinical   | HIV-         |           |
|             |                       |          |                |                        |                    | RJ    | clinical   | HIV+         |           |

*a*: the isolates typed by AFLP (Amplified Fragment Length Polymorphism) technique show the respective AFLP type; N/A: not applicable; AM: Amazonas; BA: Bahia; MG: Minas Gerais; MS: Mato Grosso do Sul; PE: Pernambuco; PR: Paraná; RJ: Rio de Janeiro; RR: Roraima; RS: Rio Grande do Sul; SP: São Paulo.